Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChariotMS
2018-005038-39Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing MAVENCLAD with Placebo (2 arms). Primary endpoint: Change in 9-hole peg test peg speed. Status: unknown.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-005038-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-005038-39.